In a Head-to-Head Battle, Brigatinib Appears to Best Crizotinib

When it comes to progression-free survival, patients appeared to fare better with brigatinib than they did with crizotinib, although the phase 3 trial has not yet concluded.

from Latest articles from Cancer Therapy Advisor News https://ift.tt/2NGBFB9